I don't believe there will be another CR, it will be a rights...

I don't believe there will be another CR, it will be a rights issue for Shareholders this close to the finish on 3 major treatments. Company still has a hefty cash balance and if BOT did need some money it would not be a significant amount,, Matt is a clever guy, for those that are concerned about any delay in commercialisation of any BOT products , keep in mind BOT have not only been attending conferences but also Guest Speakers and have presentation cards at the conferences, relationships have been built in anticipation of Positive Results..

Yes it would be fantastic if there is a suite of Patient Treatment Photo's to compliment the resulting data, that can be spoon fed to media.

Also note some new investors on the forum, welcome on board ,, just be aware there are no certainty's in Biotech and Baby Pharma,, but the risk does match the reward... I'm heavy on BOT as I personally see a lot of risk has been taken off the table over the past 2 years, but DYOR .

Generally I research 6 companies a week and in some cases still don't make an investment ,,, but when you find the one you believe in and feel comfortable with .... go with what you can afford to loose with out risking to much damage to your lifestyle.

best of luck with your investments....